SpringWorks Therapeutics in Clinical Collaboration With Janssen Biotech
September 14 2020 - 7:25AM
Dow Jones News
By Chris Wack
SpringWorks Therapeutics Inc. said Monday it has entered into a
clinical collaboration and supply agreement with Janssen Biotech
Inc. to evaluate a myeloma treatment.
The companies will research SpringWorks' investigational gamma
secretase inhibitor nirogacestat in combination with Janssen's
bispecific antibody targeting B-cell maturation antigen and CD3,
teclistamab, in patients with relapsed or refractory multiple
myeloma.
The biopharmaceutical company said that in preclinical models,
nirogacestat has been shown to increase the cell surface density of
B-cell maturation antigen and reduce levels of soluble BCMA, which
may enhance the activity of BCMA-targeted therapies, including CD3
bispecific antibodies.
Janssen will sponsor and conduct the Phase 1 study to evaluate
the safety, tolerability and preliminary efficacy of the
combination, and will assume all costs associated with the study,
other than expenses related to the manufacturing of nirogacestat.
SpringWorks Therapeutics will also form a joint oversight committee
with Janssen. The study is anticipated to begin by early 2021.
In addition to its ongoing clinical collaborations with
BCMA-directed therapies, SpringWorks said it is also currently
conducting a global Phase 3, double-blind, randomized,
placebo-controlled clinical trial to evaluate nirogacestat in
adults with progressing desmoid tumors.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 14, 2020 07:10 ET (11:10 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2023 to Sep 2024
